MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: A molecular portrait of stage 4S

Molecular Oncology

Volumn 2, Issue 3, 2008, Pages 261-271

  Bénard, Jean ^a,b   Raguénez, Gilda ^a   Kauffmann, Audrey ^a   Valent, Alexander ^a,b   Ripoche, Hugues ^a   Joulin, Virginie ^a   Job, Bastien ^a   Danglot, Gisèle ^a   Cantais, Sabrina ^a   Robert, Thomas ^b   Terrier Lacombe, Marie José ^b   Chassevent, Agnès ^c   Koscielny, Serge ^b   Fischer, Matthias ^d   Berthold, Frank ^d   Lipinski, Marc ^a   Tursz, Thomas ^b   Dessen, Philippe ^a   Lazar, Vladimir ^b   Valteau Couanet, Dominique ^b  

^a CNRS   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c CENTRE PAUL PAPIN   (France)

^d UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Metastatic neuroblastoma; Molecular signature; Stage 4S

Indexed keywords

GENE PRODUCT; MESSENGER RNA; PROTEIN MYCN; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CANCER GENETICS; CANCER REGRESSION; CANCER STAGING; CHILD; CHROMOSOME ABERRATION; CHROMOSOME LOSS; CLINICAL ARTICLE; FEMALE; GENE; GENE AMPLIFICATION; GENE CLUSTER; GENE EXPRESSION; GENOME; GROUPS BY AGE; HUMAN; INFANT; MALE; METASTASIS; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; MOLECULAR PROBE; MYCN GENE; NEUROBLASTOMA; NUCLEOTIDE SEQUENCE; PEDIATRICS; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGE FACTORS; ARTIFICIAL INTELLIGENCE; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; INFANT; MALE; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM METASTASIS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROGNOSIS; REMISSION, SPONTANEOUS;

EID: 51449083578     PISSN: 15747891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molonc.2008.07.002     Document Type: Article

References (45)

1. Ambros I.M., Bénard J., Boavida M., Bown N., Caron H., Combaret V., Couturier J., Darnfors C., Delattre O., Freeman-Edward J., et al. Quality assessment of genetic markers used for therapy stratification. J. Clin. Oncol. 21 (2003) 2077-2084
2. Asgharzadeh S., Pique-Regi R., Sposto R., Wang H., Yang Y., Shimada H., Matthay K., Buckley J., Ortega A., and Seeger R.C. Prognostic significance of gene expression profiles of metastatic neuroblastoma lacking MYCN amplification. J. Natl. Cancer Inst. 98 (2006) 1193-1201
3. Ashburner M., Ball C.A., Blake J.A., Botstein D., Butler H., Cherry J.M., Davis A.P., Dolinski J., Dwight S.S., Eppig J.T., et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25 (2000) 25-29
4. Attiyeh E.F., London W.B., Mosse Y.P., Wang Q., Winter C., Khazi D., Mc Grady P., Seeger R.C., Look A.T., Shimada H., et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N. Engl. J. Med. 353 (2005) 2243-2253
5. Berasi S., Xiu M., Yee A., and Paulson K.E. HBP1 repression of p47phox gene: cell cycle regulation via the NADPH oxidase. Mol. Cell. Biol. 24 (2004) 3011-3024
6. Bourhis J., De Vathaire F., Wilson G.D., Hartmann O., Terrier-Lacombe M.J., Boccon-Gibod L., McNally N.J., Lemerle J., Riou G., and Bénard J. Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma. Cancer Res. 51 (1991) 33-36
7. Bourhis J., Dominici C., McDowell H., Raschella G., Wilson G., Castello M.A., Plouvier E., Lemerle J., Riou G., Bénard J., and Hartmann Q. N-myc genomic content and DNA ploidy in stage IVS neuroblastoma. J. Clin. Oncol. 9 (1991) 1371-1375
8. Brazma A., Parkinson H., Sarkans U., Shojatalab M., Vilo J., Abeygunawardena N., Hollooway E., Kapushesky M., Kemmeren P., Lara G.G., et al. Array express, a public repository for microarray gene expression data at the EBI. Nucleic Acids Res. 31 (2003) 68-71
9. Brodeur G.M. Molecular basis for heterogeneity in human neuroblastomas. Eur. J. Cancer 31 (1995) 505-510
10. Brodeur G.M. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer 3 (2003) 203-216
11. Chassevent A., Jourdan M.L., Romain S., Descotes F., Colonna M., Martin P.M., Bolla M., and Spyratos F. S-phase fraction and DNA ploidy in 633 T1-T2 breast cancers: a standardized flow cytometric study. Clin. Cancer Res. 7 (2001) 909-917
12. D'Angio G., Evans A., and Koop C. Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet 1 (1971) 1046-1049
13. Eleme K., Taner S.B., Onfelt B., Collinson L.M., Mc Cann F.E., Chalupny N.J., Cosman D., Hopkins C., Magee A.I., and Davis D.M. Cell surface organization of stress-inducible proteins ULBP and MICA that stimulate human NK cells and T cells via NKG2D. J. Exp. Med. 199 (2004) 1005-1010
14. Evans A.E., D'Angio G.J., and Randolph J. A proposed staging for children with neuroblastoma. A Children's cancer study group. Cancer 2 (1971) 374-378
15. BR2 receptor subunits inhibits Ca2+ current in sympathetic neurons. J. Neurosci. 20 (2000) 2867-2874
16. Fischer M., Oberthuer A., Brors B., Kahleret Y., Skowron M., Voth H., Warnat P., Ernestus K., Hero B., and Berthold F. Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome. Clin. Cancer Res. 12 (2006) 5118-5128
17. Gasser S., and Raulet D.H. The DNA damage response arouses the immune system. Cancer Res. 66 (2006) 3959-3962
18. Gellert M. V(D)J recombination. RAG proteins, repair factors, and regulation. Ann. Rev. Biochem. 71 (2002) 101-132
19. George R.E., London W.B., Cohn S.L., Maris J.M., Kretschmar C., Diller L., Brodeur G.M., Castleberry R.P., Look A.T., et al. Hyperdiploidy plus non amplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J. Clin. Oncol. 23 (2005) 6466-6473
20. Jin S., Fan F., Fan W., Zhao H., Tong T., Blanck P., Alomo I., Rajasekaran B., and Zhan Q. Transcription factors Oct-1 and NF-YA regulate the p53-independent induction of the GADD45 following DNA damage. Oncogene 20 (2001) 2683-2690
21. Kauffmann A., Rosselli F., Lazar V., Winnepenninckx V., Mansuet-Lupo A., Dessen P., van den Oord J.J., Spatz A., and Sarasin A. High expression of DNA repair pathways is associated with metastatic melanoma patients. Oncogene 27 (2008) 565-573
22. Lastowska M., Cullinane C., Variend S., Cotterill S., Bown N., O'Neill S., Mazzocco K., Roberts P., Nicholson J., Ellershaw C., Pearson A.D., and Jackson M.S. Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors. J. Clin. Oncol. 19 (2001) 3080-3090
23. London W.B., Castleberry R.P., Matthay K.K., Look A.T., Seeger R.C., Shimada H., Thorner P., Brodeur G., Maris J.M., Reynolds C.P., and Cohn S.L. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratificationin the Children's Oncology Group. J. Clin. Oncol. 23 (2005) 6459-6465
24. Matthay K.K., Villablanca J.G., Seeger R.C., Stram D.O., Harris R.E., Ramsay N.K., Swift P., Shimada H., Black C.T., Brodeur G.M., Gerbing R.B., and Reynolds C.P. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation. N. Engl. J. Med. 341 (1999) 1165-1173
25. Meddeb M., Danglot G., Chudoba I., Vénuat A.M., Bénard J., Avet-Loiseau H., Vasseur B., Le Paslier D., Terrier-Lacombe M.J., Hartmann O., and Bernheim A. Additional copies of a 25 Mb chromosomal region originating from 17q23.1-17qter are present in 90% of high-grade neuroblastomas. Genes Chromosomes Cancer 17 (1996) 156-165
26. Monica K., Galili M., Nourse J., et al. PBX2 and PBX3, new homeobox genes with extensive homology to the human proto-oncogene PBX1. Mol. Cell. Biol. 11 (1991) 6149-6157
27. Oberthuer A., Berthold F., Warnat P., Hero B., Kahlert Y., Spitz R., Ernestus K., König R., Haas S., Eils R., Schwab M., Brors B., Westermann F., and Fischer M. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J. Clin. Oncol. 24 (2006) 5070-5078
28. Pende D., Rivera P., Marcenaro S., Chang C.C., Biassoni R., Conte R., Kubin M., Cosman D., Ferrone S., Moretta L., and Moretta A. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 62 (2002) 6178-6186
29. Rhee J., Arata A., Selleri L., Jacobs Y., Arata S., Onimaru H., and Cleary M.L. Pbx3 deficiency results in central hypoventilation. Am. J. Pathol. 165 (2004) 1343-1350
30. Rovere-Querini P., Capobianco A., Scaffidi P., Valentinis B., Catalanotti F., Giazzon M., Dumitriu I.E., Müller S., Iannacone M., Traversari C., Bianchi M.E., and Manfredi A.A. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep. 5 (2004) 825-830
31. Scaffidi P., Misteli T., and Bianchi M. Release of chromatin protein HMGB1 by necrotic cell triggers inflammation. Nature 418 (2002) 191-194
32. Schleiermacher G., Michon J., Huon I., d'Enghien C.D., Klijanienko J., Brisse H., Ribeiro A., Mosseri V., Rubie H., Munzer C., Thomas C., et al. Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification. Br. J. Cancer 97 (2007) 238-246
33. Schwab M., Alitalo K., Klempnauer K.H., Varmus H., Bishop J.M., Gilbert F., Brodeur G., Goldstein M., and Trent J. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell line and a neuroblastoma tumor. Nature (Lond) 305 (1983) 245-248
34. Schwab M., Westermann F., Hero B., and Berthold F. Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol. 4 (2003) 472-480
35. Seeger R.C., Brodeur G.M., Sather H., Dalton A., Siegel S.E., Wong K.Y., and Hammond D. Association of multiple copies of N-myc oncogene with rapid progression of neuroblastoma. N. Engl. J. Med. 313 (1985) 1111-1116
36. Soumelis V., and Liu Y.-J. Human thymic stromal lymphopoietin: a novel epithelial cell-derived cytokine and a potential key player in the induction of allergic inflammation. Springer Semin. Immun. 25 (2004) 325-333
37. Stuart L.M., Henson P.M., and Vandivier R.W. Collectins: opsonins for apoptotic cells and regulators of inflammation. Curr. Dir. Autoimmun. 9 (2006) 143-161
38. Sturn A., Quackenbush J., and Trajanoski Z. Genesis: Cluster analysis of microarray data. Bioinformatics 18 (2002) 207-208
39. Tomioka N., Kobayashi H., Kageyama H., Ohira M., Nakamura Y., Sasaki F., Todo S., Nakagawara A., and Kaneko Y. Chromosomes that show segmental loss or gain in near-diploid tumors coincide with chromosomes that show whole loss or gain in near-triploid tumors: evidence suggesting the involvement of the same genes in the tumorigenesis of high- and low-risk neuroblastomas. Genes Chromosomes Cancer 36 (2003) 139-150
40. Trochet D., Bourdeaut F., Janoueix-Lerosey II, Deville A., de Pontual L., Schleiermacher G., Coze C., Philip N., Frébourg T., Munnich A., Lyonnet S., Delattre O., and Amiel J. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am. J. Hum. Genet. 74 (2004) 761-764
41. Valteau-Couanet D., Michon J., Boneu A., Rodary C., Perel Y., Bergeron C., Rubie H., Coze C., Plantaz D., Bernard F., Chastagner P., Bouzy J., and Hartmann O. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol. J. Clin. Oncol. 23 (2005) 532-540
42. Vandesompele J., Baudis M., De Preter K., Van Roy N., Ambros P., Bown N., Brinkschmidt C., Christiansen H., Combaret V., Lastowska M., Nicholson J., O'Meara A., Plantaz D., Stallings R., Brichard B., Van den Broecke C., De Bie S., De Paepe A., Laureys G., and Speleman F. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J. Clin. Oncol. 23 (2005) 2280-2299
43. Voth H., Oberthuer A., Simon T., Kahlert Y., Berthold F., and Fischer M. Identification of DEIN, a novel gene with high expression levels in stage IVS neuroblastoma. Mol. Cancer Res. 5 (2007) 1276-1284
44. Weng L., Dai H., Zhan Y., He Y., Stepaniants S.B., and Bassett D.E. Rosetta error model for gene expression analysis. Bioinformatics 22 (2006) 1111-1121
45. Zou Z., Anisowicz A., Hendrix M.J., Thor A., Neveu M., Sheng S., Rafidi K., Seftor E., and Sager R. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 263 (1994) 526-529